The supplier of tools to drugmakers and hospitals is set up for a stronger 2026.
Get this delivered to your inbox, and more info about our products and services.
Danaher's rebound is generating optimism, but there's still work ahead for the company to hit is 2026 growth targets.
Danaher shares fell on the news that it was acquiring medtech player Masimo.
While the quarter was solid and 2026 is shaping up to be better than 2025, the progress has been slower than we would like.
Life sciences stocks are seeing a resurgence — and that's good news for Danaher.
Danaher is finally turning the corner. CNBC's Jim Cramer sees it. Wall Street does, too.
We're stepping in again as the stock continued to pull back from their February highs.
